Form 4: UTHR Director Thompson Exercises Options, Sells Shares

United Therapeutics Director Tommy G. Thompson exercised stock options and subsequently sold an equal number of common shares for a significant profit.

Summary

• Director Tommy G. Thompson of United Therapeutics Corp (UTHR) exercised 2,000 stock options on March 4, 2026, at an exercise price of $101.8 per share.
• Concurrently, Thompson sold 2,000 shares of common stock on the open market at a weighted average price of $489.4197 per share, with prices ranging from $488.95 to $489.65.
• Following these transactions, Thompson directly owns 8,480 shares of common stock.
• This direct ownership includes 880 shares of common stock expected to be issued around July 8, 2026, resulting from the July 7, 2023 vesting of Restricted Stock Units (RSUs) for which receipt was deferred.
• Additionally, Thompson indirectly owns 8,200 shares through a Trust and 5,800 shares through a Family LLC.
• After the exercise, Thompson still directly owns 2,000 derivative securities (stock options) with an exercise price of $101.8, which are exercisable from June 21, 2017, and expire on June 21, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal due to the director's sale of shares, even though it's a common practice following option exercises for personal financial planning and diversification.

Positives

• Director Thompson realized a substantial profit from exercising options at $101.8 and selling shares at an average of $489.4197, indicating a significant increase in the company's stock value since the options were granted.
• The exercise of options demonstrates the value of the company's equity compensation plan.

Negatives

• The sale of 2,000 shares by a director, even after an option exercise, could be interpreted by some investors as a signal of reduced confidence or a move to diversify personal holdings.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports insider transactions.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales by directors, are closely watched by the market as they can sometimes signal management's perception of the company's future prospects. However, in this case, the sale follows an option exercise, which is a common liquidity event for executives and directors, rather than a pure open-market sale of existing holdings.

Related Party Transactions

• The reported transactions are related party transactions as they involve a director of the company.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a minor negative signal, potentially impacting short-term sentiment.

Next Steps

• Issuance of 880 shares of common stock around July 8, 2026, from deferred RSU vesting.

Key Dates

Recommendation

While the director's sale of shares might introduce a slight negative sentiment, it's a common practice following option exercises and doesn't necessarily indicate a fundamental shift in the company's prospects. The director still retains significant direct and indirect holdings, suggesting continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor future developments without immediate action based solely on this filing.

Keywords

United Therapeutics, UTHR, Tommy G Thompson, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Director Transaction, Equity Compensation